×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: aduhelm | biogen | alzheimers | trial | amyloid beta

Aduhelm Reduced Markers for Alzheimer's Disease in Long-Term Trial: Biogen

white pills on images of the brain from an MRI
(Dreamstime)

Wednesday, 16 March 2022 09:08 AM EDT

Biogen Inc said on Wednesday patients in a long-term trial of its Alzheimer's drug Aduhelm experienced reductions in two key disease indicators after nearly two and a half years of treatment.

Biogen said that Aduhelm "significantly reduced" amyloid beta plaque levels out to week 132 of treatment and also decreased plasma levels of a protein called p-tau181 at week 128, Biogen said.

The company said that patients who at week 78 of the trial had shown reduced levels of plasma p-tau181 had less clinical decline in the extended trial than those whose plasma p-tau181 levels were not reduced earlier on.

Biogen did not provide the details of its findings.

Amyloid-beta and tau make up the plaques and tangles in the brain that are the hallmark of Alzheimer's disease.

Aduhelm, approved last year, became the first treatment to be cleared for Alzheimer's in 20 years, despite one of its two large-scale clinical trials failing to show a benefit to patients.

Regulators approved the drug on the basis of the reduction in the markers for the disease. Leading experts questioned that move and the U.S. government Medicare program has proposed that the drug's use only be allowed by patients enrolled in a new trial.

Biogen presented the data at the International Conference on Alzheimer's and Parkinson's Diseases currently underway in Barcelona.

These findings point to the potential of continued benefit of treatment, Biogen said. 

© 2022 Thomson/Reuters. All rights reserved.


Health-News
Biogen Inc said on Wednesday patients in a long-term trial of its Alzheimer's drug Aduhelm experienced reductions in two key disease indicators after nearly two and a half years of treatment. Biogen said that Aduhelm "significantly reduced" amyloid beta plaque levels out to...
aduhelm, biogen, alzheimers, trial, amyloid beta
232
2022-08-16
Wednesday, 16 March 2022 09:08 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Get Newsmax Text Alerts
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved